Lycia Therapeutics, Inc. (LYCA)
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
Industry: Biotechnology
Lycia Therapeutics Inc.
NASDAQ:LYCAHealthcare · Biotechnology
$30.00
AH Close$26.50-11.67%vs close
AH Close$26.50-11.67%vs close
Mkt Cap$1.56B
Float36.78M
O/S52.09M
Inst Own-
Dilution
Delisting Issues Timeline
Financials Summary
No financial data available.
Debt & Equity
No debt & equity data available.
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in LYCA's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
No balance sheet details available.
Income Statement
No income statement data available.
Balance Sheet
No balance sheet data available.
Cash Flow Statement
No cash flow data available.